Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNEU-PLAN: Vaxneuvance Catch-up Vaccination in Children
NCT03885934Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Primary completion
- Dec 2020
- Modality
- Split/Subunit Vaccines
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection (6 arms), sponsored by Merck & Co. Primary endpoints: Geometric Mean Concentration of Serotype-specific Immunoglobulin G, Percentage of Participants With Solicited Injection-site Adverse Events and 2 more. Started Jun 2019; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03885934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03885934.